Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-4)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00333151
First received: June 1, 2006
Last updated: January 24, 2017
Last verified: January 2017
  Purpose
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.

Condition Intervention Phase
Diabetes
Diabetes Mellitus, Type 2
Drug: liraglutide
Drug: rosiglitazone
Drug: metformin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c [ Time Frame: after 26 weeks of treatment ]

Secondary Outcome Measures:
  • body weight
  • Safety and tolerability
  • Glycaemic control

Enrollment: 576
Study Start Date: May 2006
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • Treated with oral anti-diabetic (OAD) drugs for at least 3 months
  • Treated with one or more OAD and in moderate to poor glycemic control
  • Body Mass Index (BMI) less than or equal to 45.0 kg/m2

Exclusion Criteria:

  • Treatment with insulin within the last three months prior to the trial except due to intercurrent illness, at the discretion of the Investigator
  • Any serious medical condition
  • Treatment with any drug that could interfere with glucose level
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00333151

  Hide Study Locations
Locations
United States, Arizona
Novo Nordisk Investigational Site
Goodyear, Arizona, United States, 85395
United States, California
Novo Nordisk Investigational Site
Colton, California, United States, 92324
Novo Nordisk Investigational Site
Concord, California, United States, 94520
Novo Nordisk Investigational Site
Escondido, California, United States, 92025
Novo Nordisk Investigational Site
La Jolla, California, United States, 92037
Novo Nordisk Investigational Site
Long Beach, California, United States, 90822
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90024
Novo Nordisk Investigational Site
Los Angeles, California, United States, 90057
Novo Nordisk Investigational Site
Mission Viejo, California, United States, 92691
Novo Nordisk Investigational Site
Orange, California, United States, 92869
Novo Nordisk Investigational Site
Santa Ana, California, United States, 92705
Novo Nordisk Investigational Site
Santa Barbara, California, United States, 93105
Novo Nordisk Investigational Site
Spring Valley, California, United States, 91978
United States, Connecticut
Novo Nordisk Investigational Site
New Britain, Connecticut, United States, 06050
United States, District of Columbia
Novo Nordisk Investigational Site
Washington, District of Columbia, United States, 20010
United States, Florida
Novo Nordisk Investigational Site
Fort Myers, Florida, United States, 33907
Novo Nordisk Investigational Site
Jacksonville, Florida, United States, 32204
Novo Nordisk Investigational Site
Lake Mary, Florida, United States, 32746
Novo Nordisk Investigational Site
Plantation, Florida, United States, 33324
United States, Georgia
Novo Nordisk Investigational Site
Athens, Georgia, United States, 30606
Novo Nordisk Investigational Site
Atlanta, Georgia, United States, 30032
Novo Nordisk Investigational Site
Atlanta, Georgia, United States, 30034
Novo Nordisk Investigational Site
Atlanta, Georgia, United States, 30318
Novo Nordisk Investigational Site
Powder Springs, Georgia, United States, 30127
United States, Idaho
Novo Nordisk Investigational Site
Idaho Falls, Idaho, United States, 83404-7596
United States, Illinois
Novo Nordisk Investigational Site
Peoria, Illinois, United States, 61615
United States, Indiana
Novo Nordisk Investigational Site
New Albany, Indiana, United States, 47150
United States, Iowa
Novo Nordisk Investigational Site
Des Moines, Iowa, United States, 50314
United States, Kansas
Novo Nordisk Investigational Site
Topeka, Kansas, United States, 66606
United States, Kentucky
Novo Nordisk Investigational Site
Lexington, Kentucky, United States, 40503
United States, Louisiana
Novo Nordisk Investigational Site
Baton Rouge, Louisiana, United States, 70808
Novo Nordisk Investigational Site
New Orleans, Louisiana, United States, 70121
United States, Maryland
Novo Nordisk Investigational Site
Hyattsville, Maryland, United States, 20782
United States, Mississippi
Novo Nordisk Investigational Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
Novo Nordisk Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nevada
Novo Nordisk Investigational Site
Reno, Nevada, United States, 89502
United States, New Jersey
Novo Nordisk Investigational Site
Berlin, New Jersey, United States, 08009
Novo Nordisk Investigational Site
Plainsboro, New Jersey, United States, 08536
United States, New York
Novo Nordisk Investigational Site
Albany, New York, United States, 12206
Novo Nordisk Investigational Site
Brooklyn, New York, United States, 11203
Novo Nordisk Investigational Site
Northport, New York, United States, 11768
Novo Nordisk Investigational Site
Rochester, New York, United States, 14621
United States, North Carolina
Novo Nordisk Investigational Site
Asheville, North Carolina, United States, 28803
Novo Nordisk Investigational Site
Chapel Hill, North Carolina, United States, 27599-7172
Novo Nordisk Investigational Site
Durham, North Carolina, United States, 27710
Novo Nordisk Investigational Site
Greenville, North Carolina, United States, 27834
United States, Ohio
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States, 45245
Novo Nordisk Investigational Site
Cleveland, Ohio, United States, 44195
Novo Nordisk Investigational Site
Columbus, Ohio, United States, 43203
Novo Nordisk Investigational Site
Columbus, Ohio, United States, 43212
Novo Nordisk Investigational Site
Dayton, Ohio, United States, 45406
Novo Nordisk Investigational Site
Kettering, Ohio, United States, 45429
Novo Nordisk Investigational Site
Mentor, Ohio, United States, 44060
United States, South Carolina
Novo Nordisk Investigational Site
Duncan, South Carolina, United States, 29334
United States, Tennessee
Novo Nordisk Investigational Site
Chattanooga, Tennessee, United States, 37404
United States, Texas
Novo Nordisk Investigational Site
Arlington, Texas, United States, 76014
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75230
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75231
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75246
Novo Nordisk Investigational Site
Dallas, Texas, United States, 75390-8858
Novo Nordisk Investigational Site
Houston, Texas, United States, 77025
Novo Nordisk Investigational Site
Houston, Texas, United States, 77030
Novo Nordisk Investigational Site
Lubbock, Texas, United States, 79430-8183
Novo Nordisk Investigational Site
Midland, Texas, United States, 79707
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78209
Novo Nordisk Investigational Site
San Antonio, Texas, United States, 78229
United States, Utah
Novo Nordisk Investigational Site
Salt Lake City, Utah, United States, 84102
United States, Virginia
Novo Nordisk Investigational Site
Newport News, Virginia, United States, 23606
Novo Nordisk Investigational Site
Richmond, Virginia, United States, 23294
United States, Washington
Novo Nordisk Investigational Site
Spokane, Washington, United States, 99218
United States, Wisconsin
Novo Nordisk Investigational Site
Milwaukee, Wisconsin, United States, 53209
Canada, Alberta
Novo Nordisk Investigational Site
Calgary, Alberta, Canada, T2H 2G4
Novo Nordisk Investigational Site
Edmonton, Alberta, Canada, T5J 3N4
Canada, Manitoba
Novo Nordisk Investigational Site
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, Nova Scotia
Novo Nordisk Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Novo Nordisk Investigational Site
London, Ontario, Canada, N6A 4V2
Novo Nordisk Investigational Site
Ottawa, Ontario, Canada, K1N 6N5
Novo Nordisk Investigational Site
Toronto, Ontario, Canada, M5C 2T2
Canada, Quebec
Novo Nordisk Investigational Site
Laval, Quebec, Canada, H7T 2P5
Canada
Novo Nordisk Investigational Site
Gatineau, Canada, J8T 8M1
Novo Nordisk Investigational Site
Mississauga, Canada, L5M 2V8
Novo Nordisk Investigational Site
Montreal, Canada, H2W 1R7
Novo Nordisk Investigational Site
Montreal, Canada, H3A 1A1
Novo Nordisk Investigational Site
Quebec, Canada, G1V 4G2
Novo Nordisk Investigational Site
Red Deer, Canada, T4N 6V7
Novo Nordisk Investigational Site
St John's, Canada, A1B 3V6
Novo Nordisk Investigational Site
Toronto, Canada, M5G 1X5
Novo Nordisk Investigational Site
Vancouver, Canada, V5Z 1C6
Novo Nordisk Investigational Site
Windsor, Canada, N8W 3K2
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT00333151     History of Changes
Other Study ID Numbers: NN2211-1574
Study First Received: June 1, 2006
Last Updated: January 24, 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosiglitazone
Metformin
Liraglutide
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on April 28, 2017